Our goal is to simplify the process of finding clinical studies for PKD patients in their geographic area by sending Accelerating Clinical Trials (ACT) Alert emails about ongoing studies.
In order to ensure we’re promoting studies that address our mission to find treatments and a cure for PKD, only research approved by an ethics review board (IRB) will qualify for the program.
Studies will also need to meet one of the following conditions to promoted through ACT Alerts:
- Clinical trials or activities supporting clinical trial development
- Observational studies of disease progression
- Quality of life burden research
- Clinical outcomes research
- Survey tool development or validation
Subscribe below to see which studies you may qualify for:
ADPKD ACT Alert
Designed for those diagnosed with autosomal dominant kidney disease.
ARDPKD ACT Alert
Designed for those diagnosed with autosomal recessive polycystic kidney disease.
The ADPKD Registry is a collection of individuals with autosomal dominant polycystic kidney disease (ADPKD).
By joining and completing our questionnaires, you not only help researchers learn about ADPKD, but we can also help identify your eligibility for ongoing clinical studies.
Schedule an ACT alert for your study.
Email research@pkdcure.org for more information.
Email research@pkdcure.org for more information.